A. Scalone - Academia.edu (original) (raw)
Uploads
Papers by A. Scalone
The Open Cardiovascular Medicine Journal, 2011
Introduction:Cardiorenal syndrome (CRS) is a disorder of the heart and kidney whereby interaction... more Introduction:Cardiorenal syndrome (CRS) is a disorder of the heart and kidney whereby interactions between the 2 organs can occur. We recorded the clinical features of CRS in patients consecutively admitted to an Internal Medicine ward.Patients and Methods:We retrospectively analyzed the anthropometric, history, clinical, biochemical and treatment characteristics in 438 out of 2,998 subjects (14.6%) admitted to our unit (from June 2007 to December 2009), diagnosed with CRS, according to Acute Dialysis Quality Initiative (ADQI) recommendations. Estimated glomerular filtration (eGFR) was calculated using several equations: MDRD (Modification of Diet in Renal Disease; 2 variations GFRMDRD186, GFRMDRD175), Mayo, Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) and Cockroft-Gault.Results:Mean age was 80±8 years, 222 (50.6%) were males, 321 (73.2%) were smokers, 229 (52.2%) were diabetic, 207 (47.2%) had a history of acute myocardial infarction, 167 (38.1%) had angina, 135 (30....
The Journal of Heart and Lung Transplantation, 2008
the composite of death (nϭ56), urgent (UNOS Ia) heart transplantation (nϭ11), and left ventricula... more the composite of death (nϭ56), urgent (UNOS Ia) heart transplantation (nϭ11), and left ventricular assist device implantation (nϭ2). We compared the SHFM-predicted vs. observed (method: life tables) survival for the first 5 years at 1-year increments; we also evaluated SHFM score as a predictor of mortality in this cohort. Results: Mean follow-up was 2.5Ϯ2.2 years (total time at risk 173 patient-years). The average annual mortality was 39.8% with a median survival of 2.1 years. The SHFM significantly underestimated mortality (Figure).The SHFM-predicted mean survival for this cohort was 5.0 yrs (actual: 2.5 yrs). A Cox model (bootstrapping, 1000 samples, random seed) using the SHFM score as predictor of mortality in this cohort achieved a Wald chi-square of 3.33 (pϭ0.068) and a c-statistic of 0.552. Conclusions: The SHFM score appears to be of limited prognostic value in advanced HF in patients with implantable devices.
Expert Answers to Three Key Questions Is it possible to define resistance to acetylsalicylic acid... more Expert Answers to Three Key Questions Is it possible to define resistance to acetylsalicylic acid and P2Y12 blockers at the patient’s bedside? J. W. Eikelboom, G. J. Hankey 23 What is the prevalence of resistance to aspirin and P2Y12 blockers in high-risk patients? S. D. Tomasello, D. J. Angiolillo 28 How to overcome aspirin and P2Y12 blocker resistance in secondary prevention in high-risk patients? A. Scalone, M. Valgimigli 39
Background The optimal duration of clopidogrel therapy after coronary stenting is debated because... more Background The optimal duration of clopidogrel therapy after coronary stenting is debated because of the scarcity of randomized controlled trials and inconsistencies arising from registry data. Although prolonged clopidogrel therapy after bare metal stenting is regarded as an effective secondary prevention measure, the safety profile of drug-eluting stents itself has been questioned in patients not receiving ≥12 months of dual-antiplatelet therapy.
The Open Cardiovascular Medicine Journal, 2011
Introduction:Cardiorenal syndrome (CRS) is a disorder of the heart and kidney whereby interaction... more Introduction:Cardiorenal syndrome (CRS) is a disorder of the heart and kidney whereby interactions between the 2 organs can occur. We recorded the clinical features of CRS in patients consecutively admitted to an Internal Medicine ward.Patients and Methods:We retrospectively analyzed the anthropometric, history, clinical, biochemical and treatment characteristics in 438 out of 2,998 subjects (14.6%) admitted to our unit (from June 2007 to December 2009), diagnosed with CRS, according to Acute Dialysis Quality Initiative (ADQI) recommendations. Estimated glomerular filtration (eGFR) was calculated using several equations: MDRD (Modification of Diet in Renal Disease; 2 variations GFRMDRD186, GFRMDRD175), Mayo, Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) and Cockroft-Gault.Results:Mean age was 80±8 years, 222 (50.6%) were males, 321 (73.2%) were smokers, 229 (52.2%) were diabetic, 207 (47.2%) had a history of acute myocardial infarction, 167 (38.1%) had angina, 135 (30....
The Journal of Heart and Lung Transplantation, 2008
the composite of death (nϭ56), urgent (UNOS Ia) heart transplantation (nϭ11), and left ventricula... more the composite of death (nϭ56), urgent (UNOS Ia) heart transplantation (nϭ11), and left ventricular assist device implantation (nϭ2). We compared the SHFM-predicted vs. observed (method: life tables) survival for the first 5 years at 1-year increments; we also evaluated SHFM score as a predictor of mortality in this cohort. Results: Mean follow-up was 2.5Ϯ2.2 years (total time at risk 173 patient-years). The average annual mortality was 39.8% with a median survival of 2.1 years. The SHFM significantly underestimated mortality (Figure).The SHFM-predicted mean survival for this cohort was 5.0 yrs (actual: 2.5 yrs). A Cox model (bootstrapping, 1000 samples, random seed) using the SHFM score as predictor of mortality in this cohort achieved a Wald chi-square of 3.33 (pϭ0.068) and a c-statistic of 0.552. Conclusions: The SHFM score appears to be of limited prognostic value in advanced HF in patients with implantable devices.
Expert Answers to Three Key Questions Is it possible to define resistance to acetylsalicylic acid... more Expert Answers to Three Key Questions Is it possible to define resistance to acetylsalicylic acid and P2Y12 blockers at the patient’s bedside? J. W. Eikelboom, G. J. Hankey 23 What is the prevalence of resistance to aspirin and P2Y12 blockers in high-risk patients? S. D. Tomasello, D. J. Angiolillo 28 How to overcome aspirin and P2Y12 blocker resistance in secondary prevention in high-risk patients? A. Scalone, M. Valgimigli 39
Background The optimal duration of clopidogrel therapy after coronary stenting is debated because... more Background The optimal duration of clopidogrel therapy after coronary stenting is debated because of the scarcity of randomized controlled trials and inconsistencies arising from registry data. Although prolonged clopidogrel therapy after bare metal stenting is regarded as an effective secondary prevention measure, the safety profile of drug-eluting stents itself has been questioned in patients not receiving ≥12 months of dual-antiplatelet therapy.